Global Non-alcoholic Steatohepatitis Market 2016-2020

  • ID: 3721897
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Arena Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galmed Pharmaceuticals
  • GSK
  • Novo Nordisk
  • Tobira Therapeutics
  • MORE
About Non-Alcoholic Steatohepatitis (NASH)

NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis. Conditions such as obesity, diabetes, hyperlipidemia, insulin resistance, and toxicity by drugs such as amiodarone, tamoxifen, and perhexiline maleate can cause NASH.

The analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global NASH market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of off-label drugs, originally indicated for the treatment of diabetes, obesity, and associated conditions.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global NASH Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Arena Pharmaceuticals
- AstraZeneca
- F Hoffmann-La Roche
- GSK
- Novo Nordisk
- Vivus

Other prominent vendors
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
- Immuron
- Interceptpharma
- Raptor Pharmaceutical
- Shire
- Tobira Therapeutics
- Verva
- Viking Therapeutics

Market drivers
- Increase in sedentary lifestyle
- For a full, detailed list, view the full report

Market challenges
- Limited understanding of disease pathophysiology
- For a full, detailed list, view the full report

Market trends
- Patient assistance programs
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arena Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galmed Pharmaceuticals
  • GSK
  • Novo Nordisk
  • Tobira Therapeutics
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Disease overview
  • Understanding the disease
  • Symptoms and signs
  • Pathophysiology
  • Risk factors
  • Diagnosis
  • Treatment
  • Epidemiology
  • Economic burden
PART 06: Pipeline analysis
  • Pipeline information of NASH
  • Clinical trials for NASH
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation by dosage form
  • Solid
  • Liquid
PART 09: Market segmentation by route of administration
  • Oral
  • Parenteral
PART 10: Geographical segmentation
  • Global NASH drugs market by geographical segmentation 2015-2020
  • NASH drugs market in Americas
  • NASH drugs market in US
  • NASH drugs market in EMEA
  • NASH drugs market in APAC
PART 11: Market drivers
  • Increase in sedentary lifestyle
  • Prevalence of associated health conditions
  • Promising pipeline
  • Significant unmet medical needs
PART 12: Impact of drivers

PART 13: Market challenges
  • Limited understanding of disease pathophysiology
  • Insufficient diagnostic technology for NASH
  • Stringent regulatory procedure
  • Adverse effects of drugs
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Rise in public awareness
  • Increase in strategic alliances
  • Patient assistance programs
  • Usage of off-label drugs
PART 16: Vendor landscape
  • Competitive scenario
  • Arena Pharmaceuticals
  • AstraZeneca
  • F Hoffmann-La Roche
  • GSK
  • Novo Nordisk
  • Vivus
  • Other prominent vendors
PART 17: Appendix
  • List of abbreviations
PART 18: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Conditions associated with NASH
Exhibit 03: Diagnosis of NASH
Exhibit 04: Global NASH drugs market: Pipeline portfolio
Exhibit 05: Clinical trials for NASH by development phase
Exhibit 06: Clinical trials for NASH by trial status
Exhibit 07: Global NASH drugs market 2015-2020 ($ millions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of global NASH drugs market by dosage form
Exhibit 10: Segmentation of global NASH drugs market by route of administration
Exhibit 11: Global NASH drugs market by geographical segmentation 2015
Exhibit 12: Global NASH drugs market revenue by geography 2015-2020 ($ millions)
Exhibit 13: NASH drugs market in Americas 2015-2020 ($ millions)
Exhibit 14: NASH market in US 2015-2020 ($ millions)
Exhibit 15: NASH drugs market in EMEA 2015-2020 ($ millions)
Exhibit 16: NASH drugs market in APAC 2015-2020 ($ millions)
Exhibit 17: Impact of drivers
Exhibit 18: Impact of drivers and challenges
Exhibit 19: Arena Pharmaceuticals: YoY revenue of Belviq 2013-2014 ($ millions)
Exhibit 20: Arena Pharmaceuticals: Key takeaways
Exhibit 21: AstraZeneca: Cardiovascular and metabolic diseases segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 22: Top selling products in 2014 ($ millions)
Exhibit 23: AstraZeneca: YoY growth and revenue of Bydureon 2012-2014 ($ millions)
Exhibit 24: AstraZeneca: YoY growth and revenue of Byetta 2012-2014 ($ millions)
Exhibit 25: AstraZeneca: YoY growth and revenue of Onglyza/ Komboglyze/ Komboglyze XR 2012-2014 ($ millions)
Exhibit 26: AstraZeneca: Key takeaways
Exhibit 27: Roche: Key takeaways
Exhibit 28: GSK: Key takeaways
Exhibit 29: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 30: Novo Nordisk: R&D expenditure 2014
Exhibit 31: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2012-2014 ($ millions)
Exhibit 32: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2012-2014 ($ millions)
Exhibit 33: Novo Nordisk: YoY growth and revenue of Prandin 2012-2014 ($ millions)
Exhibit 34: Novo Nordisk: Key takeaways
Exhibit 35: Vivus: YoY growth and revenue of Qsymia 2012-2014 ($ millions)
Exhibit 36: Vivus: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Arena Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galmed Pharmaceuticals
  • GSK
  • Novo Nordisk
  • Tobira Therapeutics
  • MORE
New Report Released: – Global Non-Alcoholic Steatohepatitis (NASH) Market 2016-2020

The author of the report recognizes the following companies as the key players in the global non-alcoholic steatohepatitis (NASH) market: Arena Pharmaceuticals, AstraZeneca, F Hoffmann-La Roche, GSK, Novo Nordisk, and Vivus.

Other Prominent Vendors in the market are: Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Immuron, Interceptpharma, Raptor Pharmaceutical, Shire, Tobira Therapeutics, Verva, and Viking Therapeutics.

Commenting on the report, an analyst from the research team said: “One noteworthy trend in the market is the availability of patient assistance programs. Patient assistance programs offered by vendors, designed to fit individual needs regarding liver diseases, help them attain access to medications. AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Novo Nordisk are among the companies that offer patient assistance programs, offering solutions such as co-pay assistance and coupons.”

According to the report, a key driver of market growth is an increasingly sedentary lifestyle. An unhealthy or sedentary lifestyle and the intake of high calorie food results in the accumulation of excess body fat, causing problems such as obesity, diabetes, cardiovascular problems, and liver disease, which are the associated conditions for NASH. This provides drug manufacturers with opportunities to manufacture new and effective drugs, thereby boosting the growth of the global NASH drugs market.

Further, the report states that one challenge that could severely impact market growth is the limited understanding of the disease’s pathophysiology.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- Arena Pharmaceuticals
- AstraZeneca
- F Hoffmann-La Roche
- GSK
- Novo Nordisk
- Vivus
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
- Immuron
- Interceptpharma
- Raptor Pharmaceutical
- Shire
- Tobira Therapeutics
- Verva
- Viking Therapeutics.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll